NPC1L1 and coronary artery disorder: The sensitivity analysis of the MR analysis between lowering-LDL and lowering-TG drugs with CHD showed no significant heterogeneity for the HMGCR, PCSK9, NPC1L1, ANGPTL3, and LDLR targets (Table S1).